<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/53F5B935-8A59-470F-B49C-AB17082C2BC0"><gtr:id>53F5B935-8A59-470F-B49C-AB17082C2BC0</gtr:id><gtr:name>Philips research cambridge</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC"><gtr:id>8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC</gtr:id><gtr:name>Lancaster University</gtr:name><gtr:address><gtr:line1>,</gtr:line1><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B6161E56-8D19-4789-830F-1528216FD2B6"><gtr:id>B6161E56-8D19-4789-830F-1528216FD2B6</gtr:id><gtr:name>MRC Biostatistics Unit</gtr:name><gtr:address><gtr:line1>Institute of Public Health</gtr:line1><gtr:line2>University Fovie Site</gtr:line2><gtr:line3>Robinson Way</gtr:line3><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2SR</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6161E56-8D19-4789-830F-1528216FD2B6"><gtr:id>B6161E56-8D19-4789-830F-1528216FD2B6</gtr:id><gtr:name>MRC Biostatistics Unit</gtr:name><gtr:address><gtr:line1>Institute of Public Health</gtr:line1><gtr:line2>University Fovie Site</gtr:line2><gtr:line3>Robinson Way</gtr:line3><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2SR</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/53F5B935-8A59-470F-B49C-AB17082C2BC0"><gtr:id>53F5B935-8A59-470F-B49C-AB17082C2BC0</gtr:id><gtr:name>Philips research cambridge</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC"><gtr:id>8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC</gtr:id><gtr:name>Lancaster University</gtr:name><gtr:address><gtr:line1>,</gtr:line1><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/412FAD41-315B-406A-BD7F-EB875C0D8522"><gtr:id>412FAD41-315B-406A-BD7F-EB875C0D8522</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>Wason</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UP_1302%2F4"><gtr:id>961B017C-B266-40FC-BE4D-9341666995A6</gtr:id><gtr:title>Statistical methods for next-generation clinical trials</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UP_1302/4</gtr:grantReference><gtr:abstractText>Clinical trials are used to test the effectiveness and safety of new treatments. In recent years they have become more and more expensive and have high rates of failure. Methods for reducing the cost of clinical trials and improving the chances of finding the truth are important. New technology means that new approaches to clinical trials are needed. This programme will conduct research into statistical methods for improving clinical trials. 

The programme will cover three main areas. The first is research for including the large amount of biological information that can be measured for patients. The purpose of this is that different patients may benefit more from a treatment than others: we would like to be able to find this if it is true. The second is to explore how clinical trials can be more efficient by allowing new treatments to be added as they go along. This will reduce the cost and provide opportunities to ensure patients on a trial get the most suitable treatment for them. A third area is to improve the statistical analysis of trials which use complicated ?composite endpoints? which measure several things at once. This reduces the cost of clinical trials.

By working with doctors as well as statisticians we will make sure that this research is used in real clinical trials to benefit patients and decision-makers.</gtr:abstractText><gtr:technicalSummary>The process of developing and testing a new treatment or intervention takes a long time, a lot of money, and often ends in failure. The high cost is primarily due to expensive clinical trials, which are required to show that the treatment is safe and effective. Improving the efficiency of clinical trials, to make maximum use of limited resources, is a priority research area.
This research programme will develop statistical methodology to ensure that clinical trials have the tools necessary to cope with current and future challenges. 
The first area of focus is statistical methodology for best using the increasing amount of high-dimensional biomarker data in clinical trials. With increasing availability of routinely collected biomarker data, modern clinical trials urgently require suitable methods to incorporate them prospectively. Current approaches rely on less efficient statistical methods such as testing each variant one-by-one in a logistic regression, and classifying patients as high-risk if they are positive for a certain number of biomarker. By combining novel adaptive designs and state-of-the-art high-dimensional statistical methods such as Bayesian sparse regression we can improve on this. Through working with clinicians, this novel methodology will be available for use in real trials for areas such as cardiovascular diseases and oncology.
A second area of focus is methodology for ongoing trials that test multiple treatments and biomarkers. In an ongoing trial new treatments and biomarkers are added in continually as treatments are found sufficiently promising to move to phase III trials, or are dropped due to lack of effectiveness. Some real trials are already doing this due to the considerable logistical and administrative advantages. This programme will focus on statistical issues in ongoing trials. This includes how to optimally choose decision criteria for dropping or progressing a drug to phase III and how to optimally plan phase III trials that result. Collaborations with a multidisciplinary set of statisticians and clinicians will allow us to implement developed methods in practice. 
A third area of focus is to improve the analysis of trials using composite endpoints. In this case it is possible to gain considerable power by fitting a suitable model to the data. These methods will be applied to a variety of disease areas including oncology trials, rheumatoid arthritis and lupus.</gtr:technicalSummary><gtr:fund><gtr:end>2016-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-11-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>44679</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CRUK grant</gtr:description><gtr:id>80124D4C-C3D1-4DA9-BBEE-267B63B30A2A</gtr:id><gtr:impact>With individuals at the University of Birmingham, I have successfully applied for a Cancer Research UK grant, to start in Jan 2015.</gtr:impact><gtr:outcomeId>545b7f8b5254a8.30961926-1</gtr:outcomeId><gtr:partnerContribution>Individuals at the University of Birmingham provided clinical and applied statistical expertise that has helped us jointly develop a programme of work for a grant application.</gtr:partnerContribution><gtr:piContribution>I have provided expertise in efficient statistical analysis of phase II oncology trials using the RECIST criteria.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SMARTer trial collaboration</gtr:description><gtr:id>52FE0CD7-B6D3-4B14-AD1F-F738D1291DDC</gtr:id><gtr:impact>We have submitted a paper on the trial design and a grant application to the HTA efficient trial design call (currently at outline stage).</gtr:impact><gtr:outcomeId>545b8158e9f9c5.37127388-1</gtr:outcomeId><gtr:partnerContribution>Input on the design and clinical expertise. They have also written a grant application to fund the trials.</gtr:partnerContribution><gtr:piContribution>I have provided expertise on statistical design of adaptive clinical trials to develop a suitable clinical trial design for the needs of the collaborators.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Philips Research Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Philips Research Cambridge collaboration</gtr:description><gtr:id>40B3BA0E-866E-4E1B-9CF0-88001B4B25C2</gtr:id><gtr:impact>The student (Lisa Law) started in October 2013 and has been upgraded to full Ph.D. student status in October 2014. During her time as a student, Lisa published two papers. Unfortunately Lisa chose to drop out of the PhD programme in 2016 and submitted what she had done up to that point for a MPhil degree, which she received successfully.</gtr:impact><gtr:outcomeId>545b80c1ad7fa8.17581498-1</gtr:outcomeId><gtr:partnerContribution>Individuals at Philips Research Cambridge have provided expertise on telehealth trials and have hosted the student for a research visit. They also provided a financial contribution to the EPSRC case award that funds the studentship.</gtr:partnerContribution><gtr:piContribution>I am the academic supervisor for a Ph.D. student on the subject of 'Adaptive designs for telehealth trials'</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AstraZeneca rheumatoid arthritis and SLE collaboration</gtr:description><gtr:id>EA099480-6460-4D3A-9813-BC9B14AB7DA8</gtr:id><gtr:impact>So far we have published a paper in Rheumatology, prior to Martina starting.</gtr:impact><gtr:outcomeId>58b82c7ed67cc2.97038198-1</gtr:outcomeId><gtr:partnerContribution>AstraZeneca has provided expertise from Anna Berglind and Martin Jenkins and access to clinical trial datasets in each disease. This has helped a lot with showing the methodology is useful in real life.</gtr:partnerContribution><gtr:piContribution>The Biostatistics unit funded a PhD student to work under my supervision on methodology for applying the augmented binary method, an improved analysis technique for composite outcomes, to rheumatoid arthritis and systemic lupus erythematosus. The PhD student, Martina McMenamin started in October 2016.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lancaster University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MAMS grant</gtr:description><gtr:id>CA3F4CDC-BB96-44FA-85E1-67CA09D937D7</gtr:id><gtr:impact>Multiple papers published since 2012 (recorded under publications).
Successful grant application.</gtr:impact><gtr:outcomeId>545b7e470bd1a7.63532684-1</gtr:outcomeId><gtr:partnerContribution>Dr Thomas Jaki has provided complementary expertise into the writing of papers and the grant application.</gtr:partnerContribution><gtr:piContribution>Provided input to multiple submitted papers, including two in 2013/2014, that covered multi-arm multi-stage trials and phase II oncology trials. I provided input into writing a grant that was funded by the MRC methodology research panel. I was a co-investigator on this grant.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Imaging workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9AD7E3F8-4004-488C-88AD-C4D12480DE7D</gtr:id><gtr:impact>I was invited to give a talk to a mixture of PhD students and postdocs working in imaging research on &amp;quot;Introduction to statistics for clinical trial design&amp;quot;. This was part of a course on clinical trials for that group.</gtr:impact><gtr:outcomeId>56ddaaf5f050c8.67990007</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AZ-MRC Science Symposium 2017 on 'All Data Great and Small'</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CF9ED507-9110-44FB-BE70-93B532AD03D3</gtr:id><gtr:impact>In conjunction with the AstraZeneca Biometrics Group, BSU organised a jointly sponsored science symposium on 'All Data Great and Small: Advancing clinical research through quantitative science'. 150 attendees from a cross-section of organisations came to the complimentary event, where various talks from external eminent speakers took place. 

The symposium provided an opportunity to advance knowledge and understanding on data driven research, and establish new contacts and potential new collaborations for future research. 

James Wason, Programme Leader Track, sat on the symposium organising committee - provided valuable ideas and contributions to develop the finalised agenda and format for the symposium.</gtr:impact><gtr:outcomeId>58af06b36a1386.51075475</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AB03521B-9797-4C04-ABD3-1BF5EBC13077</gtr:id><gtr:impact>Each year BSU participate in Cambridge Science Festival - members of the general public explore and discuss issues of scientific interest and concern, through a series of different events. The festival also aims to raise aspirations by encouraging young people to consider a career in science, technology, engineering or mathematics.

BSU take part over two full days - 'Science Saturday' and the 'Cambridge Biomedical Campus' day. The unit presents a stand with 4 - 5 interactive activities that each communicate a basic statistical method or idea, representing one of the four research themes in the unit. Each year a new activity is developed and delivered requiring scientific input from staff and students across the unit. Over the two days, BSU engage with approximately 500 adults and children who visit the festival.</gtr:impact><gtr:outcomeId>56ddace61a6002.22559233</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media enquiry - 'Trust Me I'm a Doctor'</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DB4D0EFE-D79C-48BB-A117-5BFFC5EF2FE7</gtr:id><gtr:impact>James Wason, Programme Leader Track, provided background research on clinical trials research for BBC 2 documentary 'Trust Me I'm a Doctor'</gtr:impact><gtr:outcomeId>58aefaaca44590.57634440</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Armitage Lectures</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9F8275E7-5142-4977-B2E9-A6A7A52725E3</gtr:id><gtr:impact>Annual workshop and lecture created and hosted by the MRC Biostatistics Unit, to honour the immense contributions of Professor Peter Armitage who was at the unit from 1947 to 1961, and whose work is recognised throughout the world as achieving a successful balance between methodological rigour and applied commonsense, to which all statisticians aspire. An eminent medical statistician visits for a week and works with members of the unit. The highlight is the Armitage Lecture, where more than 100 delegates attend. This event raises the unit research profile and creates new collaborations.</gtr:impact><gtr:outcomeId>58b6f88e9b8d88.83216260</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.mrc-bsu.cam.ac.uk/news-and-events/armitage-lectureships-and-workshops/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>5818</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Gates Foundation - Dora Pereira</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>5AF82504-0ADB-4826-AA0A-B49F09635D02</gtr:id><gtr:outcomeId>56deb10971a3b7.42619169</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7746</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>Health Technology Assessment</gtr:description><gtr:end>2021-12-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>E27CD8F4-4C5C-44A6-B225-0C68647563A5</gtr:id><gtr:outcomeId>58b82f60802594.49450307</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>96860</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Biometrika Fellowship</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Biometrika Trust</gtr:fundingOrg><gtr:id>B176BC01-DE79-4B28-B1D7-996A39A35B40</gtr:id><gtr:outcomeId>56deafa9c63343.61144201</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>23279</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCL -Peter Fonagy</gtr:description><gtr:end>2020-10-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>2DF614EF-A258-417E-8861-FB5606F9F9EA</gtr:id><gtr:outcomeId>56deaff57f8971.41003144</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>56487</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC- Alistair Coles</gtr:description><gtr:end>2020-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>CFD7842F-0563-4DA6-96A8-DA881E604115</gtr:id><gtr:outcomeId>56deb094324069.26966838</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>146451</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC/NIHR Methodology Research Programme</gtr:department><gtr:description>Methodology Research Programme</gtr:description><gtr:end>2020-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1D94C4BA-9F24-4D99-96CE-A58000A3C5EF</gtr:id><gtr:outcomeId>58b83095e01d56.38588598</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>New adaptive design mentioned as 'research highlight' in Nature Reviews Clinical Oncology</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9295BEAA-9D7E-4DE0-A92D-CEE6F2574B70</gtr:id><gtr:outcomeId>56dea48621e2b1.31664627</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.nature.com/nrclinonc/journal/v12/n9/full/nrclinonc.2015.138.html</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>This is a publically available R package for finding optimal group-sequential clinical trial designs. It is available from the CRAN repository (which involves validation steps).</gtr:description><gtr:id>0E2CD40F-AEFF-4FDE-A5EE-E9404CCE5552</gtr:id><gtr:impact>The software package description and documentation has been published in the Journal of Statistical Software.</gtr:impact><gtr:outcomeId>56dda0f616ac76.40653060</gtr:outcomeId><gtr:title>OptGS R package</gtr:title><gtr:type>Software</gtr:type><gtr:url>https://cran.r-project.org/web/packages/OptGS/index.html</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7628F8AB-9C57-471B-A43D-12C2C334DF4A</gtr:id><gtr:title>Stepped wedge cluster randomized controlled trial designs: a review of reporting quality and design features.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb33c74748bce8e9ac10c620100d80d1"><gtr:id>eb33c74748bce8e9ac10c620100d80d1</gtr:id><gtr:otherNames>Grayling MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58ac049a3f4479.14736198</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B023910F-EBC6-4FC3-8EBF-1A8CD449EE4B</gtr:id><gtr:title>OptGS: An R package for finding near-optimal group-sequential designs</gtr:title><gtr:parentPublicationTitle>Journal of Statistical Software</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b664eef7d277554ea667867605a230b5"><gtr:id>b664eef7d277554ea667867605a230b5</gtr:id><gtr:otherNames>Wason J.M.S.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>15487660</gtr:issn><gtr:outcomeId>56cf271801d4a5.84906552</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9627209-2035-408E-B19F-C9375FD795C5</gtr:id><gtr:title>Multisystemic therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): a pragmatic, randomised controlled, superiority trial.</gtr:title><gtr:parentPublicationTitle>The lancet. Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c37f0470435950f0fee95c893bbfa15a"><gtr:id>c37f0470435950f0fee95c893bbfa15a</gtr:id><gtr:otherNames>Fonagy P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2215-0366</gtr:issn><gtr:outcomeId>5a616e7defa666.52079736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E47CAD0-3D1D-49A8-A2A5-6CA7AD226ED6</gtr:id><gtr:title>Response-adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?</gtr:title><gtr:parentPublicationTitle>Pharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b06c40cded9b34659ad19265e1011f7"><gtr:id>1b06c40cded9b34659ad19265e1011f7</gtr:id><gtr:otherNames>Villar SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1539-1604</gtr:issn><gtr:outcomeId>5a616a0ee8b2a1.18337540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FF9EA3A-FA47-4E5C-B6B0-588387B8B6B7</gtr:id><gtr:title>Some recommendations for multi-arm multi-stage trials.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/667b3a7c3073fc54ec79ec58d0024d3b"><gtr:id>667b3a7c3073fc54ec79ec58d0024d3b</gtr:id><gtr:otherNames>Wason J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>58ac04998ead07.29361537</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF3ACC1B-2695-43E1-8FE1-A81A66F86B0E</gtr:id><gtr:title>Use of an embedded, micro-randomised trial to investigate non-compliance in telehealth interventions.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30e9485f28233c88b1acfd370269bc4c"><gtr:id>30e9485f28233c88b1acfd370269bc4c</gtr:id><gtr:otherNames>Law LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>58ac0499d076b2.94531349</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>041DF06D-F01E-4162-AE0A-837E1C682A99</gtr:id><gtr:title>The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>58ac04996d52b8.16571693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F15103D0-D5CB-45CB-A9E6-405599D533B9</gtr:id><gtr:title>The longitudinal effect of ejaculation on seminal vesicle fluid volume and whole-prostate ADC as measured on prostate MRI.</gtr:title><gtr:parentPublicationTitle>European radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68af30591ea79179094038aaf2a8f768"><gtr:id>68af30591ea79179094038aaf2a8f768</gtr:id><gtr:otherNames>Barrett T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0938-7994</gtr:issn><gtr:outcomeId>5a616d6ac15804.30585876</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDFD164F-30D5-4B33-B865-7BE276B7FDCC</gtr:id><gtr:title>Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/673294f4973975b6cd4e42fcd9584292"><gtr:id>673294f4973975b6cd4e42fcd9584292</gtr:id><gtr:otherNames>Gerety EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>56cf26e4a63d61.39171468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FF61182-FAD8-484F-A881-3F8C1EA95950</gtr:id><gtr:title>Response-adaptive randomization for multi-arm clinical trials using the forward looking Gittins index rule.</gtr:title><gtr:parentPublicationTitle>Biometrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b06c40cded9b34659ad19265e1011f7"><gtr:id>1b06c40cded9b34659ad19265e1011f7</gtr:id><gtr:otherNames>Villar SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-341X</gtr:issn><gtr:outcomeId>56cf276eabd268.91056257</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC7D40ED-514C-42D7-BBC2-7513EA70542A</gtr:id><gtr:title>The power of phase II end-points for different possible mechanisms of action of an experimental treatment.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>560aa1503415f0.79474785</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD9BC06B-616E-49F2-8844-BBC1927ECF55</gtr:id><gtr:title>Training nurses in a competency framework to support adults with epilepsy and intellectual disability: the EpAID cluster RCT.</gtr:title><gtr:parentPublicationTitle>Health technology assessment (Winchester, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/977472350f95002d92596137c29ad444"><gtr:id>977472350f95002d92596137c29ad444</gtr:id><gtr:otherNames>Ring H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1366-5278</gtr:issn><gtr:outcomeId>5a9552b202f1b5.03893470</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C512F50-D767-45F8-B39E-364BCEFBAA1F</gtr:id><gtr:title>A multi-stage drop-the-losers design for multi-arm clinical trials.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/667b3a7c3073fc54ec79ec58d0024d3b"><gtr:id>667b3a7c3073fc54ec79ec58d0024d3b</gtr:id><gtr:otherNames>Wason J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>58ac0499aff2e3.71682357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0704CF3-1BD4-4103-A252-FC0FD4AD31D3</gtr:id><gtr:title>A Bayesian adaptive design for biomarker trials with linked treatments.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>56cf26a838da39.29341736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1213A6DA-7FCA-4AE5-AEFF-494E2E3BF18D</gtr:id><gtr:title>Group sequential designs for stepped-wedge cluster randomised trials.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb33c74748bce8e9ac10c620100d80d1"><gtr:id>eb33c74748bce8e9ac10c620100d80d1</gtr:id><gtr:otherNames>Grayling MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>5a616c41d41888.80482411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4000D2B2-27F3-4238-B373-7C51F6549358</gtr:id><gtr:title>Adaptive designs in clinical trials: why use them, and how to run and report them.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b4ce11d600cea298d5911acf3126187"><gtr:id>7b4ce11d600cea298d5911acf3126187</gtr:id><gtr:otherNames>Pallmann P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>5aa3cddc535c57.71326047</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8303DE78-00ED-4D95-8285-DDD9B0FB5ED2</gtr:id><gtr:title>HLA associations in South Asian multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/336e1a709128f07102217664888bfc24"><gtr:id>336e1a709128f07102217664888bfc24</gtr:id><gtr:otherNames>Pandit L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn><gtr:outcomeId>56deae46312a00.01323673</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFE89BEB-64E4-4B24-A917-AEA06F258285</gtr:id><gtr:title>Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f02a7b6725658f4917fa96d1aa872d11"><gtr:id>f02a7b6725658f4917fa96d1aa872d11</gtr:id><gtr:otherNames>Lin CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>5a35c8ce6ecf81.70410159</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA02AD3D-0846-4EF7-9AA6-B1617614884F</gtr:id><gtr:title>Multi-armed Bandit Models for the Optimal Design of Clinical Trials: Benefits and Challenges.</gtr:title><gtr:parentPublicationTitle>Statistical science : a review journal of the Institute of Mathematical Statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b06c40cded9b34659ad19265e1011f7"><gtr:id>1b06c40cded9b34659ad19265e1011f7</gtr:id><gtr:otherNames>Villar SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0883-4237</gtr:issn><gtr:outcomeId>56cf27e2562704.06103081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE72347A-0628-4339-9041-5D6B792AB9BB</gtr:id><gtr:title>Imaging biomarker roadmap for cancer studies.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5261e64d77ae945d18be26d2f9a33824"><gtr:id>5261e64d77ae945d18be26d2f9a33824</gtr:id><gtr:otherNames>O'Connor JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>58ac049919fd72.92085946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA390A8F-6395-4B36-A674-7C80E9697D3E</gtr:id><gtr:title>Two-stage phase II oncology designs using short-term endpoints for early stopping.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/246931942fbf1c1ce7efc72225069e11"><gtr:id>246931942fbf1c1ce7efc72225069e11</gtr:id><gtr:otherNames>Kunz CU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>56cf273c63d001.16703385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EA8B8AE-864E-4B86-ADD9-A535EEB6BF06</gtr:id><gtr:title>Noninterventional statistical comparison of BTS and CHEST guidelines for size and severity in primary pneumothorax.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/046740bad40d4cdac74a9378aaf5d6e9"><gtr:id>046740bad40d4cdac74a9378aaf5d6e9</gtr:id><gtr:otherNames>Nikolic MZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>56deae46137606.86840550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>073ADD71-81BC-4F48-98C6-BBC955BDF7EC</gtr:id><gtr:title>Improving the power of clinical trials of rheumatoid arthritis by using data on continuous scales when analysing response rates: an application of the augmented binary method.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>58ac04993eb104.39463669</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F754162-89CA-4427-8B54-5508553629E8</gtr:id><gtr:title>An adaptive design for updating the threshold value of a continuous biomarker.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fdd8aa3b4f9e8e52982ed321d045a80"><gtr:id>9fdd8aa3b4f9e8e52982ed321d045a80</gtr:id><gtr:otherNames>Spencer AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>58ac0498e55354.71298593</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A75B51B-1205-4E5B-B616-9A3D6461E353</gtr:id><gtr:title>Improving outcomes in adults with epilepsy and intellectual disability (EpAID) using a nurse-led intervention: study protocol for a cluster randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/977472350f95002d92596137c29ad444"><gtr:id>977472350f95002d92596137c29ad444</gtr:id><gtr:otherNames>Ring H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58ac049a012433.53633334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>025D6577-6CC6-4D3C-B0C0-E3302F8CDAAC</gtr:id><gtr:title>A review of statistical designs for improving the efficiency of phase II studies in oncology.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>56cf27a4c81533.37240527</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UP_1302/4</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>